日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

克唑替尼辅助治疗用于高危葡萄膜黑色素瘤患者根治性治疗后

Khan, Shaheer; Lutzky, Jose; Shoushtari, Alexander N; Jeter, Joanne; Marr, Brian; Olencki, Thomas E; Cebulla, Colleen M; Abdel-Rahman, Mohamed; Harbour, J William; Sender, Naomi; Nesson, Alexandra; Singh-Kandah, Shahnaz; Hernandez, Susana; King, Jeanelle; Katari, Manpreet S; Dimapanat, Lyssa; Izard, Stephanie; Ambrosini, Grazia; Surriga, Oliver; Rai, Alex J; Chiuzan, Codruta; Schwartz, Gary K; Carvajal, Richard D

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

双互补位抗体-药物偶联物用于治疗 MET 表达癌症,包括对 MET 通路阻断无反应的癌症

John O DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C Franklin, Frank J Delfino, Shu Mao, Feng Zhao, Jason T Giurleo, Marcus P Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W Retter, Rabih Slim, Tara M Young, William C Olson, Ga

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

转移性葡萄膜黑色素瘤生存的转录分析提名NRP1作为治疗靶点

Riyue Bao, Oliver Surriga, Daniel J Olson, Jacob B Allred, Carrie A Strand, Yuanyuan Zha, Timothy Carll, Brian W Labadie, Bruno R Bastos, Marcus Butler, David Hogg, Elgilda Musi, Grazia Ambrosini, Pamela Munster, Gary K Schwartz, Jason J Luke

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance

在GNAQ突变型葡萄膜黑色素瘤中鉴定出参与细胞生长、肿瘤细胞侵袭和MEK耐药性的独特MEK依赖性基因

Ambrosini, Grazia; Pratilas, Christine A; Qin, Li-Xuan; Tadi, Madhavi; Surriga, Oliver; Carvajal, Richard D; Schwartz, Gary K